IGEM:Caltech/2007/Project/Riboregulator

From OpenWetWare
Revision as of 22:56, 8 October 2007 by Katpak (talk | contribs)
Jump to navigationJump to search

iGEM 2007

Home        People        Project        Protocols        Notes        Changes       


Riboregulator

RNA Background

RNA has traditionally been considered a carrier of information between the gene and the final protein product. However, recent evidence is accumulating for alternate functions for RNA - namely, the use of RNA molecules as regulatory elements in the cell. Examples include ribozymes, siRNA, and riboswitches.

Riboregulators

New insights into this regulatory role of RNA have allowed for engineering new RNA molecules which control cell behavior interactions with other RNAs or with small molecule ligands. One such engineering approach which enables post-transcriptional control of gene expression is the riboregulator developed by Collins and coworkers. The riboregulator is composed of two interacting parts, a cis-repressive sequence and a trans-activating sequence. The cis sequence is placed directly upstream of the ribosome binding site (RBS) of the gene regulated by the riboregulator and is complimentary to the RBS. This sequence forms a stem-loop structure in the 5’-untranslated region of the mRNA which prevents ribosome binding and thus translation. The trans RNA is complementary to the cis sequence. When the trans RNA is present, it binds to the cis sequence, the RBS site becomes exposed, and the ribosome can bind and translate the mRNA.

Riboregulator Integration in Our Phage/E.coli System

The riboregulator determines what happens to the cell once it is infected by phage. We aimed to design three types of riboregulated systems (one for each protein N, Q, and Cro). For instance, for the N protein-regulated system, the phage genome would have a mutant version of the N gene as well as an N gene suppressed with a cis-repressive sequence would be additionally integrated into the genome. When the phage infects a wild-type E.coli cell, nothing should happen. However, when it infects a cell with the trans-activating non-coding RNA, the cell should lyse because the RBS of the N gene is no longer sequestered by the cis-repressed RNA loop.

Riboregulator Design

Our riboregulators consist of two interacting parts: cis and trans. The cis sequence is located downstream from the promoter to a gene of interest and upstream of the ribosome binding site (RBS). This cis sequence is complementary to the RBS and forms a stem-loop at the 5’ end of the mRNA after transcription, thus blocking ribosome binding and translation. Gene expression is turned on with a trans noncoding RNA. This trans sequence is produced from another promoter in a different plasmid and targets the cis-repressed RNA with high specificity. When the trans transcript is available, it binds to the cis region and thus opens the RBS for ribosome docking and subsequent translation. The cis repressive sequences are approximately 50 base pairs and do not alter the reading frame of the native gene. The trans RNA is approximately 90 base pairs and contains a nucleotide sequence that is complementary to the cis RNA. RNAstructure3 software was used to predict the secondary structure as well as the free energy of the cis and trans elements and their interactions.


Experiments with Riboregulators

In order to have a working system in which phage infection outcome is controlled, the expression of genes under the control of a riboregulator must be determined. Once the amount of N, Q, or Cro necessary to switch the system from lysis to lysogeny (or nothing) is determined, an appropriate riboregulator can be integrated into the system which allows for the correct amount of protein to be made in the trans-activating cells.

Before combining the phage protein expression with the riboregulator part of the system, it is necessary to engineer various riboregulators and determine the percent of protein (green fluorescent protein or GFP) in the presence and absence of trans-RNA. By quantifying the riboregulated GFP system, we could then apply the results to each protein.

Status and Future Plans

Deborah and Kat - please fill in here